Page 16 - CIBERES-2015-eng

Research Groups
F. Pérez Vizcaino
5
5
J. Villar
29
24
E. Monsó
24
9
J Ruiz Cabello
9
7
J. Ortín
13
7
L. Blanch
34
15
M. Menéndez
6
6
F. Barbé
27
13
28 2
29 10
30 5
31 2
32 2
33 2
34 2
35 12
COOPERATION:
No. of intraCIBER publications 2015: 161 No. of interCIBER publications 2015: 87
Patents:
APPLIED FOR:
System for integrating the filtrate/concentration and detection of biological samples by immuno- logical methods on porous surfaces. Dr. Noemí Parrega (Dr. Monsó’s group). (CSIC 75% /IGTP 17.5% /CIBER 6% / UAB 2.5% ). Integrated filter holder in which mechanical filtration of the sam- ples is carried out to concentrate the biological material on the filtration membrane and a culture is made in order to perform microbiological de- tection by methods based on biomolecule affinity, keeping its watertightness during concentration and detection.
PATENTS EXTENDED TO PCT IN 2015:
• “Method for predicting response to continuous positive air pressure treatment” Dr. Manuel Sánchez de la Torre (Group Dr. Barbé) (IRB Llei- da 53,85%/ CIBER 38,46%/ Fundación Hospi- tal la Fe 7,69%).
• “Micellar nanoparticles containing antitumor- alglycosides” . DR. Hugo Groult (Group Dr. Ruiz-Cabello) CNIC 67%/ CIBER 33%.
• “Methods and systems for providing oxygen to a patient”. Dra. Molina y Dr. Rossell (Groups Dr. Picado Y Dr. Monsó). IDIBELL57,5%/ UAB 37,5%/ CIBERES 5%.
• “Bimodal fluorophore-labeled liposomes and associated methods and systems”. Dr. Car- los Pérez –Medina (Group Dr. Ruiz-Cabello) MSKCC (50%), Mount Sinai (35%), and CIBER 7.5%/ CNIC (7.5%).
Guías clínicas:
• ESCMID guideline for the diagnosis and treat- ment of biofilm infections 2014.
• A clinical clasification of the acute respiratory distress syndrome for predicting outcome and guiding medical therapy.
• Nebulized Antibiotic Treatment of Respiratory Infections in Critically Ill Mechanically Ventila- ted Patients.
• Clinical Practice Guide of the Study Group in Mycobacteria Infections (GEIM) of the Socie- dad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC).
• Consensus statement from the 2014 Interna- tional Microdialysis Forum.
• Spanish consensus on the prevention and treatment of Pseudomonas aeruginosa bron- chial infections in cystic fibrosis patients.
• SEPAR protocol for control and follow-up of home respiratory therapies. Syndrome of sleep apnoea-hypopnea.
• MACVIA-ARIA sentinel Network for Allergic Rhinitis, MASK-Rhinitis. The new generation guideline implementation.
• Member of the GOLD Board of Directors.
• SEPAR regulation on muscular dysfunction of patients with chronic obstructive pulmonary disease.
16 I Annual report 2015 I CIBERES